Elan Pharmaceuticals, Inc.

Prothena Biosciences Limited

Biogen Ma Inc.

Janssen Alzheimer Immunotherapy

Wyeth

Elan Pharma International Limited

Athena Neurosciences, Inc.

Neuralab Limited

Theodore A Yednock

Kenneth Flanagan

Michael A Pleiss

Dale Bernard Schenk

Jeanne E Baker

Andrei William Konradi

Robin McDaid Barbour

Yue Liu

Stephen Jed Tam

Christopher Michael Semko

Jenifer Lea Smith

Russell E Rydel

Julie Elizabeth Taylor

Sarah Wright

Elizabeth Messersmith

Nicki Vasquez

Eugene D Thorsett

Jose William Saldanha

Lisa Claire McConlogue

Stephen B Freedman

Ivan Lieberburg

Kate Dora Games

Irene Griswold-Prenner

Pamela S Keim

Olivier J Leger

Irene Griswald Prenner

Tan Hua

George Shopp

Jeanne Baker

Mary M Bendig

Tarran S Jones

Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.

Methods of treating inflammatory and autoimmune diseases with natalizumab

A method of chronically reducing a patient's pathological inflammation via the administration of an agent that specifically binds to an alpha-4 integrin or a dimer comprising an alpha-4 integrin is disclosed. The agent provided must have a binding affinity such that administration is sufficient to suppress pathological inflammation, and the agent is administered chronically to provide long-term suppression of pathological inflammation.

Administration of agents for the treatment of inflammation

The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin &#x3b1;4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.

Anti-Laminin4 antibodies specific for LG4-5

Anti-laminin4 antibodies specific for LG4-5

Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin &#x3b1;-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.

Anti-MCAM antibodies and associated methods of use

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of A&#x3b2; in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease. Preferred agents including N-terminal fragments of A&#x3b2; and antibodies binding to the same.

Prevention and treatment of amyloidogenic disease

Disclosed are conjugates exhibiting VLA-4 antagonistic properties. Certain of these conjugates also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. The conjugates of this invention are characterized as containing more than one VLA-4 inhibiting compound covalently attached to a bio-compatible polymer, such as polyethylene glycol. Conjugates of the invention are defined by formula I, wherein A, B, and q are described in the specification. Such conjugates are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis, and myocardial ischemia. The conjugates can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.

Multimeric VLA-4 antagonists comprising polymer moieties

The present invention features methods and compositions for inhibiting amyloidogenic protein toxicity, inhibiting formation of an amyloidogenic protein deposit and/or treating amyloidogenic diseases by administering a pharmaceutically effective amount of one or more agents that bind an integrin or an integrin subunit.

Methods of inhibiting amyloid toxicity

Growing community of inventors

Forest Knolls, CA, United States of America

Theodore A Yednock